Home/ Stocks/ NXTC

NextCure, Inc. Common Stock

NXTC XNAS

$6.66 +4.48 (+205.52%) ▲ 15-min delayed

Open

$9.24

High

$9.90

Low

$5.76

Volume

96.78M

Market Cap

$7.87M

About NextCure, Inc. Common Stock

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 40 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-9,796,000	$-1.87
FY 2025	$0	$-55,844,000	$-19.65
Q3 2025	$0	$-8,624,000	$-3.22
Q2 2025	$0	$-26,808,000	$-11.29

TickerDaily Coverage

Why Is NextCure, Inc. Common Stock (NXTC) Stock Up 314.2% Today?

Penny Stocks Marcus Rivera · 3h ago

NextCure Inc. (NXTC) stock exploded 314.2% to $9.24 on massive volume Tuesday after announcing a...

View All Coverage →

Get NXTC Alerts

Stay ahead with breaking news, price alerts, and expert analysis on NextCure, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.